enGene Holdings Inc. Common Stock Total Assets
enGene Holdings Inc. Common Stock total assets. Based on the latest financial reports, enGene Holdings Inc. Common Stock (ENGN) holds total assets worth $288.32 Million USD as of July 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see enGene Holdings Inc. Common Stock (ENGN) total market value for the company's overall valuation and market capitalisation.
Total Assets of enGene Holdings Inc. Common Stock (2021–2025)
Total assets of enGene Holdings Inc. Common Stock from 2021 to 2025. This chart illustrates how enGene Holdings Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. See enGene Holdings Inc. Common Stock share price for real-time trading data and today's change.
enGene Holdings Inc. Common Stock - Asset Composition Analysis
enGene Holdings Inc. Common Stock Total Assets Breakdown (October 2025)
enGene Holdings Inc. Common Stock total assets breakdown as of October 2025. enGene Holdings Inc. Common Stock's total assets of $288.32 Million consist of 90.9% current assets and 9.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 22.7% |
| Accounts Receivable | $2.23 Million | 1.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ENGN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: enGene Holdings Inc. Common Stock's current assets represent 90.9% of total assets in 2025, an increase from 1.2% in 2021.
- Cash Position: Cash and equivalents constituted 22.7% of total assets in 2025, up from 0.8% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 1.0% of total assets.
enGene Holdings Inc. Common Stock Competitors by Total Assets
Key competitors of enGene Holdings Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
enGene Holdings Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.21 | 10.34 | 4.79 |
| Quick Ratio | 10.21 | 10.34 | 4.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $250.69 Million | $190.87 Million | $1.24 Million |
enGene Holdings Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between enGene Holdings Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.55 |
| Latest Market Cap to Assets Ratio | 0.49 |
| Asset Growth Rate (YoY) | -28.8% |
| Total Assets | $221.47 Million |
| Market Capitalization | $108.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values enGene Holdings Inc. Common Stock's assets below their book value (0.49x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: enGene Holdings Inc. Common Stock's assets decreased by 28.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for enGene Holdings Inc. Common Stock (2021–2025)
The table below shows the annual total assets of enGene Holdings Inc. Common Stock from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | $221.47 Million | -28.83% |
| 2024-10-31 | $311.17 Million | +257.84% |
| 2023-10-31 | $86.96 Million | -34.14% |
| 2022-10-31 | $132.04 Million | +0.45% |
| 2021-10-31 | $131.45 Million | -- |
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. T… Read more